Wednesday 13th June 2012
|Text too small?|
Ebos Group, which bought animal health and pet food products maker Masterpet last year, has settled on a slightly smaller funding line than previously indicated as part of its new banking syndicate.
The Christchurch-based company entered into a new finance facility with ANZ National Bank and Bank of New Zealand worth $135 million with staggered expiry dates between August 2014 and August 2016, it said in a statement. The medical equipment distributer previously flagged the new facility would allow borrowings of up to $145 million, according to its first-half report.
"Whilst there has been no major change in the overall group bank debt levels, the new syndicated facilities provide for greater flexibility for future growth," the company said.
The new funding line replaces a $99 million facility and a $60 million bridging loan that expired at the end of April. Ebos took out the short-term loan to partially fund the Masterpet acquisition. As at Dec. 31, had total bank debt of $148.1 million.
The shares fell 0.3 percent to $7.53 in trading today, and have gained 20 percent since the purchase was announced at the end of December. The stock is rated a 'buy' according to a consensus of two analysts compiled by Reuters, with a median target price of $7.85.
No comments yet
Ebos still hungry for acquisitions after $1.1 bln Symbion deal, Waller says
Ebos meets prospectus forecast with 5.5 percent gain in FY profit
Ebos shareholders approve $1.1 billion purchase of Symbion
Ebos grabs scale with $1.1 bln purchase of Aussie pharma distributor Symbion
Ebos kicks tyres on potential acquisitions
Ebos lifts profit by 19%, targets growth in animal health
Ebos backs off British purchase, evaluates "significant" Australasian asset
Ebos reports higher profit, looks for acquisitions
Daily ShareChat: EBOS Group